Benefit of intensified consolidation therapy with and without allogeneic BMT for subsets of high-risk ALL in trial ALL-BFM 90.

被引：0
|
作者：
Reiter, A
Ebell, W
Schrappe, M
Harbott, J
Ludwig, WD
Klingebiel, T
Zintl, F
Henze, G
Gadner, H
Welte, K
Riehm, H
机构：
[1] HANNOVER MED SCH,D-3000 HANNOVER,GERMANY
[2] BERLIN UKRV,BERLIN,GERMANY
[3] UNIV GIESSEN,GIESSEN,GERMANY
[4] HUMBOLDT UNIV BERLIN,BERLIN,GERMANY
[5] UNIV TUBINGEN,D-72074 TUBINGEN,GERMANY
[6] UNIV JENA,D-6900 JENA,GERMANY
[7] ST ANNA CHILDRENS HOSP,A-1090 VIENNA,AUSTRIA
来源：
BLOOD | 1997年 / 90卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：997 / 997
页数：1
相关论文
共 50 条
  • [1] Outcome of allogeneic BMT in high-risk childhood T-Cell acute lymphoblastic leukemia (HR-T-ALL) compared to treatment with chemotherapy alone: results from trials ALL-BFM 90 and ALL-BFM 95
    Schrauder, A
    Reiter, A
    Zimmermann, M
    Klingebiel, T
    Mann, G
    Welte, K
    Schrappe, M
    BONE MARROW TRANSPLANTATION, 2002, 29 : S7 - S8
  • [2] INTENSIFIED CONSOLIDATION THERAPY FOR HIGH-RISK ALL PATIENTS
    HOELZER, D
    THIEL, E
    LOFFLER, H
    BUCHNER, T
    GANSER, A
    HEIL, G
    KURRLE, E
    HEIMPEL, H
    KOCH, P
    LIPP, T
    KABOTH, W
    KUSE, R
    KUCHLER, R
    SODOMANN, H
    MASCHMEYER, G
    FREUND, M
    DIEDRICH, H
    VONPALESKE, A
    WEH, J
    KOLB, H
    MULLER, U
    BROSS, K
    FUHR, G
    GASSMANN, W
    GERECKE, D
    KRESS, M
    BUSCH, FW
    NOWROUSIAN, RM
    SCHNEIDER, W
    AUL, C
    RUHL, H
    BARTELS, H
    HARMS, F
    WEISS, A
    LOFFLER, B
    GLOCKNER, W
    FULLER, H
    PRALLE, H
    HO, AD
    BONFERT, B
    EMMERICH, B
    BRAUMANN, D
    BRENNERSERKE, M
    PLANKER, M
    STRAIF, K
    MEYER, P
    GREIL, R
    PETSCH, S
    GORG, C
    GRUNEISEN, A
    ONKOLOGIE, 1988, 11 (01): : 18 - 24
  • [3] Risk-oriented treatment of childhood ALL: Favorable outcome despite reduced intensity of treatment in trial ALL-BFM 90.
    Schrappe, M
    Reiter, A
    Sauter, S
    Gadner, H
    Lampert, F
    Ritter, J
    Pluess, J
    Niethammer, D
    Havers, W
    Doerffel, W
    Zimmermann, M
    Welte, K
    Riehm, H
    BLOOD, 1997, 90 (10) : 2488 - 2488
  • [4] Treatment results from trials ALL-BFM 90 and ALL-BFM 95 in high-risk childhood T-cell acute lymphoblastic leukemia (HR-T-ALL)
    Schrauder, A
    Reiter, A
    Riehm, H
    Zimmermann, M
    Klingebiel, T
    Mann, G
    Schrappe, M
    LEUKEMIA, 2001, 15 (03) : 492 - 492
  • [5] Major Improvement of Outcome in Pediatric High-Risk Acute Lymphoblastic Leukemia by Addition of BFM Chemotherapy Element "Phase IB": A Comparative Data Analysis of Trials ALL-BFM 95 and ALL-BFM 2000
    Moericke, Anja
    Schrauder, Andre
    Zimmermann, Martin
    Mann, Georg
    Attarbaschi, Andishe
    Koehler, Rolf
    Panzer-Gruemayer, Renate
    Stanulla, Martin
    Cario, Gunnar
    Reiter, Alfred
    Niggli, Felix
    Bartram, Claus R.
    Schrappe, Martin
    BLOOD, 2011, 118 (21) : 652 - 653
  • [6] Treatment results in childhood acute lymphoblastic leukemia with a modified ALL-BFM'90 protocol: lack of improvement in high-risk group
    Sackmann-Muriel, F
    Felice, MS
    Zubizarreta, PA
    Alfaro, E
    Gallego, M
    Rossi, J
    Cygler, AM
    LEUKEMIA RESEARCH, 1999, 23 (04) : 331 - 340
  • [7] Prospective evaluation of minimal residual disease (MRD) in high-risk childhood acute lymphoblastic leukemia in the ongoing trial ALL-BFM 2000
    Schrauder, A
    Flohr, T
    Zimmermann, M
    Koch, D
    Stanulla, M
    Lauten, M
    Welte, K
    Bartram, C
    Schrappe, M
    BONE MARROW TRANSPLANTATION, 2002, 30 : S60 - S60
  • [8] Chemotherapy with reduced intensity can provide 90% event-free survival in standard risk ALL: Results from trial ALL-BFM 95.
    Schrappe, M
    Gadner, H
    Reiter, A
    Zimmermann, M
    Ludwig, WD
    Harbott, J
    Klingebiel, T
    Niemeyer, C
    Riehm, H
    BLOOD, 2003, 102 (11) : 222A - 222A
  • [9] MRD-kinetics in children with high-risk ALL reveal insights into development of resistance and allow further refinement of treatment stratification strategies:: report from trial ALL-BFM 2000
    Schrauder, A.
    Stanulla, M.
    Flohr, T.
    Cario, G.
    Koeler, R.
    Panzer-Gruemayer, R.
    Schaefer, B.
    Zimmermann, M.
    Moericke, A.
    Peters, C.
    Bartram, C. R.
    Schrappe, M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 : 60 - 60
  • [10] Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: Results from ALL-BFM 90 and 95
    Schrauder, Andre
    Reiter, Alfred
    Gadner, Helmut
    Niethammer, Dietrich
    Klingebiel, Thomas
    Kremens, Bernhard
    Peters, Christina
    Ebell, Wolfram
    Zimmermann, Martin
    Niggli, Felix
    Ludwig, Wolf-Dieter
    Riehm, Hansjoerg
    Welte, Karl
    Schrappe, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (36) : 5742 - 5749
12345